CN1879783A - 一种治疗糖尿病的药物 - Google Patents
一种治疗糖尿病的药物 Download PDFInfo
- Publication number
- CN1879783A CN1879783A CNA2006100804944A CN200610080494A CN1879783A CN 1879783 A CN1879783 A CN 1879783A CN A2006100804944 A CNA2006100804944 A CN A2006100804944A CN 200610080494 A CN200610080494 A CN 200610080494A CN 1879783 A CN1879783 A CN 1879783A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- diabetes
- treatment
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 23
- 241000208340 Araliaceae Species 0.000 claims abstract description 5
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 5
- 235000008434 ginseng Nutrition 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 235000013305 food Nutrition 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 229930188824 alisol Natural products 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 23
- 239000008103 glucose Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 14
- 210000002700 urine Anatomy 0.000 description 12
- 235000009508 confectionery Nutrition 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 208000004880 Polyuria Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 206010020710 Hyperphagia Diseases 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 206010036067 polydipsia Diseases 0.000 description 6
- 208000022530 polyphagia Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000008454 Hyperhidrosis Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010043458 Thirst Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- -1 take very convenient Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗糖尿病的药物,具体是一种治疗糖尿病的中草药制剂,本发明是由下述重量配比的原料制成的药剂:人参25-35,黄芪20-40,山药15-35,鲜野生地10-20,沙苑子15-35,泽泻盐炙10-20,五味子3-9,桑螵蛸3-9,山茱萸制12-24,玄参6-12,三七6-9,白芍12-24,丹参12-24,刺五加10-15,本发明药物治疗糖尿病疗效好,具有降血糖、降血脂、降血粘度,改善微循环,增强肌体免疫等作用。
Description
技术领域
本发明涉及一种治疗糖尿病的药物,具体是一种治疗糖尿病的中草药制剂。
技术背景
糖尿病是一种内分泌代谢疾病,因胰岛素分泌绝对或相对不足以及靶细胞对胰岛素敏感性降低,引起糖蛋白质、脂肪及继发的水、电解质代谢紊乱,临床上表现为烦渴、多尿、多食、多饮、消瘦、疲乏等,糖尿病是严重危害人类健康的常见多发病。目前世界上糖尿病患者超过一亿人,病死率仅次于恶性肿瘤及心血管病,是危及人类生命健康的第三大疾病。
发明内容
本发明所要解决的技术问题是提供一种具有降低血糖、尿糖、血脂、促进糖的代谢、补气益阴,增强机体免疫,毒副作用小的糖尿病中草药制剂。
本发明采用如下技术方案:
本发明是由下述重量配比的原料制成的药剂:
人参25-35 黄芪20-40 山药15-35 鲜野生地10-20
沙苑子15-35 泽泻盐炙10-20 五味子3-9 桑螵蛸3-9
山茱萸制12-24 玄参6-12 三七6-9 白芍12-24 丹参12-24
刺五加10-15
本发明所说的药剂是任何一种药剂学上所说的剂型。
本发明积极效果如下:糖尿病又称消渴病,消渴病一般分上消、中消、下消。以烦渴多饮为上消,服以清热,润躁养阴之剂。多食善饮为中消,服予凉膈散化之剂。淋漓多尿为下消,用滋阴补肾之剂治疗,本发明针对消渴病这一规律,以清热解毒,养阴益气为治疗之根本,根据祖国医学对糖尿病治疗的辩证施治理论,结合中药现代药理和临床研究基础,从祖国医药宝库中通过优选传统中药,经多年临床试用研制而成,本发明药物具有滋肾补肺、补气益阴、降血糖、降血脂、促进糖的代谢、改善微循环、增强机体免疫之功效。
本发明药物制剂可以是任何一种药剂学上所说的剂型,如散剂、蜜丸、口服液、胶囊等。最好是制成药粉剂后装入胶囊,服用非常方便,胶囊服药方法:每日3次,每次2-3粒,每粒0.5-1克。
本发明药物中:
人参:甘、微苦、微温,归心、脾经,大补元气,补脾益肺,生津安神;
黄芪:甘、微温,归脾、肺经,补气升阳、益卫固表,利水消肿,托疮生肌;
山药:甘、平,归脾、肺、肾经,益气滋阴,补脾肺肾,固精止带;
鲜野生地:甘、苦、寒,归心、肝、肺经,清热凉血,养阴生津
沙苑子:甘、温,归肝、肾经,补精固表,养肝明目;
泽泻:甘、淡寒,归肾、膀胱经,利尿渗湿,泄热;
五味子:酸、甘、温,归肺、心、肾经,敛肺滋肾,生津敛汗,涩精止泻,宁心安神;
桑螵蛸:甘、咸、平,归肝、肾经,固精缩尿,补肾助阳;
山茱萸(制):酸、涩、微温,归肝、肾经,补益肝肾,收敛固涩;
玄参:苦、甘、咸、寒,归肺、胃、肾经,清热凉血,滋阴解表
三七:甘、微苦、温,归肝、胃经,化瘀止血,活血定痛
白芍:苦、酸、甘、微寒,归肝、脾经,养血调经,平肝止痛,敛阴止汗;
丹参:苦、微寒,归心、脾经,活血调经,凉血消痛、安神;
刺五加:辛、苦、温,归肝、肾经;具有抗疲劳作用,能兴奋性腺、肾上腺,加速糖元形成,降低血糖。
本发明药物同目前国内常用的治疗糖尿病药相比,具有以下优点:
1、本发明药物为中药制剂,毒副作用小,目前国内治疗糖尿病的药物大多选用传统的化学药物及胰岛素替代疗法,用药不当会引起毒副作用,久用还会引起肝肾损害,而本发明的中药均为平和无毒之药,临床证明其毒副作用很小。
2、西药治疗糖尿病只治标不治本,而本发明采用中医理论,达到阴阳、表里、虚实平衡、起到降尿糖、降血糖、降血脂作用。
3、本发明药物药源广,价格低,适宜推广应用。
通过13年近2000名病人的临床观察的验证,本发明药物治疗糖尿病疗效好,具有降血糖、降血脂、降血粘度,改善微循环,增强肌体免疫等作用。
为表明本发明对糖尿病的治疗效果和药物的安全性,进行了140例的临床观察,140例病人中,男73例,女67例,最大年龄69岁,最小年龄39岁,平均54岁,病程最长18年,最短4年,有合并症者15例,无合并症者125例。
疗效标准:痊愈:口渴、多饮、多食、多尿、身体消瘦症状完全消失,血糖、尿糖检验正常,停药后1年不复发;显效:口渴、多饮、多食、多尿、身体消瘦症状基本消失,尿糖,血糖正常;有效:症状缓解,血糖、尿糖较原来下降;无效:症状无改善,血糖、尿糖无明显变化。
结果:痊愈20例,显效72例,有效35例,无效13例,总有效率90.71%。
典型病例:
病例一:刘某,男,54岁,山东省冠县人,在冠县医院诊断为II型糖尿病,病史7年,采用饮食治疗,口服降糖药疗效不理想来诊,口渴多饮、多食、多尿,身体明显消瘦,体重46公斤,无力、多汗,空腹血糖11.7mmol/L,尿糖+++,2000年6月服用本发明药物胶囊,一日3次,一次3粒,饭前服,血糖下降后逐渐减量,达到控制量维持治疗,连续服用三个月后,症状消失,体重增至54公斤,空腹血糖5.4mmol/L,尿糖(一),后继续服药四个月,目前天天干农活,停药后随访2年无复发。
病例二:杜某某,男,43岁,河北省邯郸市人,糖尿病史4年,口渴多饮,尿频量多,多食,大便干燥,眩晕、无力、身体消瘦,曾服用降糖灵、消渴丸、美迪康等,血糖始终在17.6mmol/L,尿糖++++,给予本发明药物一日二次,一次2粒,用药期间据症情加减,连续服用2月后,症状消失,空腹血糖5.28mmol/L,尿糖(一),体力、精神与正常人无异,继续服用本发明药物4个月,停药后随访1年3个月无复发。
病例三:李某,男,63岁,河北省大名人,在某医院诊断为II型糖尿病,病史6年,烦渴易激,饮水量增加,食多,乏力体重减轻,大便难,血糖9.6mmol/L,尿糖++,服用本发明药物,一日3次,一次2粒,饭前服,血糖下降后,逐渐减量,达到控制量维持治疗,连续服用4个月后,症状消失,血糖(空腹)5.8mmol/L,尿糖(一),继续服用本发明药物4个月,停药后一年半无复发。
具体实施方式:本发明实施例如下表所示:
| 组份 | 含量(重量份数比) | ||
| 人参 | 25 | 30 | 35 |
| 黄芪 | 40 | 20 | 30 |
| 山药 | 20 | 15 | 35 |
| 鲜野生地 | 15 | 20 | 10 |
| 沙苑子 | 20 | 35 | 15 |
| 泽泻盐炙 | 15 | 10 | 20 |
| 五味子 | 6 | 3 | 9 |
| 桑螵蛸 | 9 | 6 | 3 |
| 山茱萸制 | 18 | 12 | 24 |
| 玄参 | 12 | 8 | 6 |
| 三七 | 7.5 | 9 | 6 |
| 白芍 | 12 | 18 | 24 |
| 丹参 | 24 | 12 | 16 |
| 刺五加 | 10 | 12.5 | 15 |
Claims (2)
1、一种治疗糖尿病的药物,其特征在于是由下述重量配比的原料制成的药剂:
人参25-35 黄芪20-40 山药15-35 鲜野生地10-20
沙苑子15-35 泽泻盐炙10-20 五味子3-9 桑螵蛸3-9
山茱萸制12-24 玄参6-12 三七6-9 白芍12-24 丹参12-24
刺五加10-15
2、根据权利要求1所述的一种治疗糖尿病的药物,其特征在于所说的药剂是任何一种药剂学上所说的剂型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100804944A CN100509025C (zh) | 2006-05-18 | 2006-05-18 | 一种治疗糖尿病的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100804944A CN100509025C (zh) | 2006-05-18 | 2006-05-18 | 一种治疗糖尿病的药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1879783A true CN1879783A (zh) | 2006-12-20 |
| CN100509025C CN100509025C (zh) | 2009-07-08 |
Family
ID=37518284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100804944A Expired - Fee Related CN100509025C (zh) | 2006-05-18 | 2006-05-18 | 一种治疗糖尿病的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100509025C (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101637579B (zh) * | 2009-09-08 | 2011-04-27 | 江春德 | 一种治疗糖尿病的中药及其制备方法 |
| CN101352512B (zh) * | 2007-07-27 | 2011-06-22 | 北京亚东生物制药有限公司 | 一种治疗糖尿病的中药组合物及其制备方法 |
| CN102688434A (zh) * | 2012-06-20 | 2012-09-26 | 于海英 | 一种治疗糖尿病的中药 |
| CN104815166A (zh) * | 2015-05-13 | 2015-08-05 | 鲁东大学 | 一种治疗糖尿病的中药组合物及其制备和应用 |
-
2006
- 2006-05-18 CN CNB2006100804944A patent/CN100509025C/zh not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101352512B (zh) * | 2007-07-27 | 2011-06-22 | 北京亚东生物制药有限公司 | 一种治疗糖尿病的中药组合物及其制备方法 |
| CN101637579B (zh) * | 2009-09-08 | 2011-04-27 | 江春德 | 一种治疗糖尿病的中药及其制备方法 |
| CN102688434A (zh) * | 2012-06-20 | 2012-09-26 | 于海英 | 一种治疗糖尿病的中药 |
| CN104815166A (zh) * | 2015-05-13 | 2015-08-05 | 鲁东大学 | 一种治疗糖尿病的中药组合物及其制备和应用 |
| CN104815166B (zh) * | 2015-05-13 | 2018-01-12 | 鲁东大学 | 一种治疗糖尿病的中药组合物及其制备和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100509025C (zh) | 2009-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1148211C (zh) | 用于治疗充血性心力衰竭的药物 | |
| CN102743540A (zh) | 联合降糖方 | |
| CN101690789B (zh) | 一种治疗糖尿病的中药制剂 | |
| CN101485834B (zh) | 治疗糖尿病的中药 | |
| CN101062256A (zh) | 消渴中药组合物 | |
| CN101279034B (zh) | 一种内服和外用结合治疗糖尿病的组合中药及制备方法 | |
| CN102886019A (zh) | 中药降糖膏药 | |
| CN100509025C (zh) | 一种治疗糖尿病的药物 | |
| CN103007159B (zh) | 校正胰岛功能的中药制剂 | |
| CN103638389A (zh) | 一种治疗糖尿病的中药组合物 | |
| CN101983688B (zh) | 一种治疗糖尿病的药物及其制备方法 | |
| CN1245197C (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 | |
| CN1308024C (zh) | 一种治疗糖尿病的药物及其制备方法 | |
| CN104474103A (zh) | 一种天然植物降糖剂及其制备方法 | |
| CN1277577C (zh) | 治疗脑血栓病的中药及其应用 | |
| CN100339119C (zh) | 一种治疗糖尿病的降糖中药制剂 | |
| CN109078157A (zh) | 一种抗肿瘤药物及其制备方法 | |
| CN106668390B (zh) | 一种治疗早中期甲状腺功能亢进症的中药组合物 | |
| CN1309412C (zh) | 一种治疗艾滋病的药物组合物及其制备方法 | |
| CN101987188A (zh) | 一种用于预防和治疗高血脂症的生物中成药 | |
| CN1745835A (zh) | 糖尿病丸及其配方 | |
| CN100369621C (zh) | 一种治疗糖尿病的药物 | |
| CN1970058A (zh) | 一种治疗糖尿病的中药制剂 | |
| CN119679897A (zh) | 一种辅助治疗阳虚水泛型水肿的穴位贴敷中药组合物及其制备方法 | |
| CN104758889A (zh) | 一种治疗糖尿病的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090708 Termination date: 20150518 |
|
| EXPY | Termination of patent right or utility model |